Pfizer and BioNTech Submit Information on Vaccine for Children 5 to 11

WASHINGTON — Pfizer and BioNTech introduced on Tuesday that they’d submitted knowledge to the Meals and Drug Administration that the businesses stated confirmed their coronavirus vaccine is protected and efficient in kids ages 5 to 11.

The businesses stated they’d submit a proper request to regulators to permit a pediatric dose of their vaccine to be administered in the US within the coming weeks. Comparable requests shall be filed with European regulators and in different international locations.

The announcement, coming as U.S. faculties have resumed amid a ferocious wave of the extremely contagious Delta variant, brings many dad and mom one other step nearer to the probability of a coronavirus vaccine for his or her kids.

Requested on Tuesday when the vaccine is perhaps cleared for youngsters, Pfizer’s chief govt, Dr. Albert Bourla, stated he didn’t wish to pre-empt regulators.

“It’s not applicable for me to remark how lengthy F.D.A. would take to evaluation the information,” Dr. Bourla stated in an appearance at the Atlantic Festival, hosted by The Atlantic magazine. “They should take as much time as they think is appropriate for them.” He added that an authorization around Halloween, as some health officials have suggested could be possible, was “one of the options, and it’s up to the F.D.A.”

Just over a week ago, Pfizer and BioNTech announced favorable results from their clinical trial with more than 2,200 participants in that age group. The F.D.A. has said it will analyze the data as soon as possible. Dr. Peter Marks, the agency’s top vaccine regulator, said recently that barring “surprises,” an authorization could come in “a matter of weeks, not months” after the companies submitted data.

The companies said last week that their vaccine had been shown to be safe and effective in low doses in children ages 5 to 11, offering hope to parents in the United States who are worried that a return to in-person schooling has put children at risk of infection.

About 28 million children ages 5 to 11 would be eligible for the vaccine in the United States, far more than the 17 million ages 12 to 15 who became eligible for the vaccine in May.

But it is not clear how many in the younger cohort will be vaccinated. Inoculations among older children have lagged: Only about 43 percent of children ages 12 to 15 have been fully vaccinated in the United States, compared with 67 percent of adults, according to federal data.

Source link